DRUG STUDY

Generic Name Classification and Indication Mechanism of Contraindications Side effects Nursing Considerations
sevelamer Category action
Brand Name Frequent (20%– Baseline assessment
Renagel A. Chemical: Polymeric Binds with Possesses Hypersensitivity to 11%): Obtain baseline
Renvela phosphate binder dietary nonselective sevelamer. Bowel Infection, pain, chemistries, esp. serum
phosphorus in beta-blocking obstruction. hypotension, calcium, phosphate; assess
Available dosage
B. Therapeutic: GI tract, and alpha- Cautions: diarrhea, for bowel
 Powder for Electrolyte modifier, allowing adrenergic Dysphagia, severe dyspepsia, obstruction.
Oral antihyperphosphatemia phosphorus to be blocking GI tract motility nausea,
Suspension agent. eliminated activity. disorders, major GI vomiting. Intervention/evaluation
(Renvela): 0.8 through normal Causes tract surgery. Occasional Monitor serum phosphate,
g/pack, 2.4 C. Pregnancy: Category C digestive vasodilation. (10%–1%): bicarbonate, chloride,
g/pack. process, Headache, calcium.
 Tablets decreasing Therapeutic constipation,
(Renagel): 400 serum Effect: hypertension, Patient/family teaching
mg, 800 mg. phosphorus Hypertension: increased • Take with meals, swallow
(Renvela): 800 level. Reduces cardiac cough. tablets whole; do not chew,
mg. output, exercise- crush, dissolve, or divide
Therapeutic induced tablets.
Effect: tachycardia, Adverse • Report persistent
Decreases reflex orthostatic Reactions headache, nausea,
incidence of tachycardia; vomiting, diarrhea,
hypercalcemic reduces Thrombosis hypotension.
episodes in pts peripheral occurs rarely.
receiving vascular
Route PO calcium acetate resistance. HF:
Frequency OD treatment. Decreases
pulmonary
capillary wedge
pressure, heart
rate, systemic
vascular
resistance;
increases stroke
volume index.